NMRA (Neumora Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neumora Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neumora Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-50.34 Mil. Neumora Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Neumora Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Neumora Therapeutics's current FCF Yield % is -109.65%.

The historical rank and industry rank for Neumora Therapeutics's FCF Margin % or its related term are showing as below:

NMRA's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -140.87
* Ranked among companies with meaningful FCF Margin % only.

Neumora Therapeutics FCF Margin % Historical Data

The historical data trend for Neumora Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neumora Therapeutics FCF Margin % Chart

Neumora Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

Neumora Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Neumora Therapeutics's FCF Margin %

For the Biotechnology subindustry, Neumora Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neumora Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neumora Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Neumora Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neumora Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-182.936	/	0
	=	%

Neumora Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-50.34	/	0
	=	%

Neumora Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Neumora Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neumora Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neumora Therapeutics Inc (NAS:NMRA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472

Website

https://www.neumoratx.com

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Executives

Michael Lee Milligan	officer: See Remarks	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Robert A. Lenz	officer: Head of R&D	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Paul L Berns	director	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Joshua Pinto	officer: Chief Financial Officer	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Daljit Singh Aurora	officer: Chief Strategy Officer	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, Llc	10 percent owner	8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Amgen Inc	10 percent owner	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Henry O Gosebruch	director, officer: President & CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Arch Venture Fund Xii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xii, L.p.	10 percent owner	8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Alaa Halawa	director	C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472